erk

ERK-IN-2, an ERK2 inhibitor, exhibits an IC50 value of 1.8 nM. At doses greater than 10 μM, it may induce off-target toxicity and/or activity [1].

ERK-CLIPTAC is a PROTAC (PROteolysis TArgeting Chimera) molecule designed to induce the degradation of Extracellular signal-Regulated Kinase (ERK) [1].

ERK-IN-4 is a cell-permeable ERK inhibitor with potential antiproliferative effects for the study of diseases caused by immune dysfunction.

ERK-IN-3 (ASN007 free base) is a potent and orally active inhibitor of ERK. It inhibits ERK1/2 with low single-digit nM IC50 values. It can be used for the research of cancers driven by RAS mutations.

ERK-IN-2 free base, an inhibitor of ERK2, demonstrates potent efficacy with an IC50 value of 1.8 nM. However, doses exceeding 10 μM may result in off-target toxicity and/or activity.

ERK-IN-3 benzenesulfonate is a potent and orally active inhibitor of ERK . ERK-IN-3 benzenesulfonate inhibits ERK1/2 with low single-digit nM IC 50 values. ERK-IN-3 benzenesulfonate can be used for the research of cancers driven by RAS mutations.

ERK Inhibitor II (Negative control) effectively blocks extracellular signal-regulated kinase (ERK) and interferes with insulin receptor activation, serving as a useful tool in diabetes research.

ERK-IN-6 (compound 6g) serves as a potent anti-proliferative agent against esophageal squamous cell carcinoma (ESCC), inducing apoptosis through the ERK pathway. This compound has potential applications in ESCC research [1].

CK2/ERK8-IN-1 (TMCB) is a dual inhibitor of casein kinase 2 (CK2) (Ki: 0.25 µM) and ERK8 (IC50s: 0.50 μM) with pro-apoptotic efficacy. CK2/ERK8-IN-1 also binds to PIM1, DYRK1A, and HIPK2 (Kis: 8.65 µM, 11.9 µM, and 15.25 µM).

ERK5-IN-6 is a potent inhibitor of ERK5 kinase.ERK5-IN-6 exhibits antiproliferative activity, anticonvulsant activity, and antitumor activity, and can be used in the study of central nervous system-related disorders.

Rineterkib (ERK-IN-1) is an inhibitor of RAF and ERK1/2 activating mutations in the MAPK pathway.

ERK5-IN-5 is a potent extracellular signal-regulated kinase 5 (ERK5) inhibitor with anticancer activity and potential anticonvulsant activity that inhibits A549 cell proliferation.

ERK1/2 Inhibitor 5, a potent suppressant of the ERK1/2 pathway, is instrumental in the mitogen-activated protein kinase (MAPK) signal transduction pathway, where extracellular signal-regulated kinase (ERK) serves as a critical component of the MAPK family. This compound holds promise for the investigation or mitigation of cancer, inflammation, or various proliferative diseases[1].

ERK1/2 inhibitor 8 is a potent inhibitor of ERK that acts on ERK2 (IC50: 0.48 nM).

ERK5-IN-2 is an orally active, sub-micromolar, selective ERK5 inhibitor with IC50s of 0.82 μM, 3 μM for ERK5 and ERK5 MEF2D, respectively.

ERK5-IN-1 is a potent ERK5 inhibitor (IC50: 87 nM). It also inhibits LRRK2[G2019S] (IC50: 26 nM).

ERK1/2 inhibitor 7 is a potent inhibitor of ERK, acting on ERK2 (IC50: 0.94 nM).

ERK1/2 Inhibitor 9 (Probe 1), a covalent antagonist of ERK1/2, exhibits sub-micromolar efficacy in cellular assays (A375 GI50=0.47 μM) and facilitates the reduction of phospho-ERK1/2 levels. When conjugated with trans-cyclo-octene (TCO) and Tz-Thalidomide (tetrazine-tagged Thalidomide), it forms the corresponding ERK-CLIPTAC, promoting targeted ERK1/2 degradation [1].

ERK1/2 Inhibitor 3, a potent inhibitor of ERK1/2, plays a crucial role in the signal transduction pathway by targeting the Mitogen-activated protein kinase (MAPK) family, specifically the extracellular signal-regulated kinase (ERK). Given its significant impact, this compound holds promise for research or prevention efforts related to cancer, inflammation, or other proliferative diseases[1].

ERK1/2 inhibitor 6 is a potent inhibitor of ERK1/2. ERK1/2 inhibitor 6 has shown potential for the study or prevention of cancer, inflammation or other proliferative diseases.

ERK1/2 inhibitor 5 is a potent inhibitor of ERK1/2. ERK1/2 inhibitor 5 has the potential to investigate or prevent cancer, inflammation or other proliferative diseases.

ERK5-IN-3 is a selective and potent inhibitor of ERK5 (extracellular signal-associated kinase 5) (IC50: 6 nM). ERK5-IN-3 exhibits anti-proliferative effects on Hela cells (IC50: 31 nM).

ERK5-IN-4 (compound 34b) is a powerful and specific inhibitor of extracellular signal-related kinase 5 (ERK5) activity. It effectively inhibits both the full-length ERK5 and the truncated ERK5 (ERK5 ΔTAD) kinase activity in HEK293 cells with IC50 values of 77 nM and 300 nM, respectively [1].

p44/42 MAPK (Erk1/2) (137F5) Rabbit mAb #4695R is a useful organic compound for research related to life sciences and the catalog number is T64587.

Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (20G11) Rabbit mAb #4376R is a useful organic compound for research related to life sciences and the catalog number is T64608.

ERK1/2 inhibitor 1 is a potent, orally bioavailable ERK1/2 inhibitor, showing 60% inhibition at 1 nM and an IC50 of 3.0 nM against ERK1 and ERK2, respectively.

PERK-IN-4 is a potent and selective PERK inhibitor with an IC50 value of 0.3 nM.PERK-IN-4 can be used in the study of cancer and neurological disorders.

PERK-IN-6 is a novel and highly potent PERK inhibitor (IC50:2.5 nM).

AMG PERK 44 is an orally active and selective PERK inhibitor (IC50: 6 nM) that induces autophagy.AMG PERK 44 inhibits GCN2 (IC50: 7300 nM) and B-Raf (IC50 >1000 nM) and can be used in the study of cancer.

VX-11e (TCS ERK 11e) is a potent, selective, and orally bioavailable ERK(Extracellular Signal-Regulated Kinase) inhibitor; antitumor agent.

STE-MEK1(13), a cell-permeable ERK1/2 inhibitor with IC50 values ranging from 13 to 30 μM, impedes the phosphorylation of ERK1/2, as demonstrated in studies [1] [2].

Temuterkib (LY3214996) is a potent and selective, orally available inhibitor of the extracellular signal-regulated kinase (ERK) 1 and 2, with potential antineoplastic activity.

L-161982 is a selective antagonist of EP4 receptor. L-161982 could inhibit PGE2-induced ERK phosphorylation and cell proliferation of HCA-7 cells. L-161982 could alleviate collagen-induced arthritis in mice.

MRTX1133 is a KRAS G12D inhibitor (KD=0.2 pM) that is potent, selective, and non-covalent. MRTX1133 exhibits inhibitory activity against KRAS G12D-mutated tumors, but not against KRAS wild-type tumors.

SCH 772984 is a potent inhibitor of ERK1 ERK2 (IC50: 4 1 nM) and has only weak inhibitory for other 300 tested kinases.

Butein (2’,3,4,4’-tetrahydroxy Chalcone), a plant polyphenol, is isolated from Rhus verniciflua. It can inhibit the activation of protein tyrosine kinase, NF-κB and STAT3, and also can inhibit EGFR.

DCLK1-IN-1 is a selective and in vivo-compatible chemical probe of the DCLK1 kinase domain .

1. Hypericin (Cyclosan) has antineoplastic activity. 2. Hypericin has antibiotic and antiviral activities. 3. Hypericin has antidepressive activity through inhibiting monoamine oxidase enzyme. 4. Hypericin inhibits RANKL-mediated osteoclastogenesis via affecting ERK signalling in vitro and suppresses wear particle-induced osteolysis in vivo.

Allicin exerts antioxidant, bactericidal, anti-cancer, anti-inflammatory activities, it exerts an inhibitory immunomodulatory effect on intestinal epithelial cells. Allicin could significantly inhibit vascular smooth muscle cells' proliferation and migration induced by insulin, which may be related to the inhibition of the activation of ERK signal path. Allicin is beneficial in reducing blood cholesterol, triglycerides levels and systolic blood pressure in hypercholesterolemic rats, it may beneficially affect two risk factors for atherosclerosis-hyperlipidemia and hypertension.

Astragaloside IV (AS-IV), an active component isolated from Astragalus membranaceus, suppresses the activation of ERK1/2 and JNK, and downregulates matrix metalloproteases (MMP)-2, (MMP)-9 in MDA-MB-231 breast cancer cells. Astragaloside IV is a bioactive saponin first isolated from the dried plant roots of the genus Astragalus, which is used in traditional Chinese medicine.1 It dose-dependently inhibits human adenovirus type 3 (HAdV-3) in A549 cells (IC50 = 23 μM; LC50 = 865 μM).It inhibits replication of HAdV-3 and decreases HAdV-3-induced apoptosis. It has diverse protective effects for the cardiovascular, immune, digestive, and nervous systems. In particular, it reduces myocardial infarct size in dogs when administered prior to coronary ligation and reduces reperfusion arrhythmias in isolated rat hearts.

Magnolin reduces the renal oxidative stress, suppresses caspase-3 activity, and increases Bcl-2 expression in vivo and in vitro. Magnolin has anti-inflammatory and antioxidative effects.

1. Farrerol has antioxidative activity.2. Farrerol modulates TAP and BNBD5 gene expression in mammary gland, enhances bMEC defense against S. aureus infection and could be useful in protection against bovine mastitis. 3. Farrerol inactivates KEAP-1 or act

Berkeleylactone E, a macrolide antibiotic [1], exhibits antimicrobial properties.

ZINC12409120 (R-4584) is a selective ERK inhibitor.ZINC12409120 inhibits ERK with an IC50 of 5.0 μM.ZINC12409120 inhibits ERK activity by interfering with FGF23:α-Klotho interaction.

Gardenin A shows neurotrophic effects via activating MAPK/ERK, PKC, and PKA. Gardenin A exhibits antidepressant, anticonvulsant and anxiolytic effects.

Motixafortide TFA(664334-36-5,Free) (BKT140 TFA) is an antagonist of CXCR4 with IC50 of ～1 nM. It induces the apoptosis of AML blasts by down-regulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression.

Epieriocalyxin A can suppress Caco-2 colon cancer cell growth. It could be a potential drug for colon cancer therapy in the future.

FSLLRY-NH2 TFA is a is a protease-activated receptor 2 (PAR2) inhibitor. Reverses taxol-induced mechanical allodynia, heat hyperalgesia and PKC activation in ICR mice. Blocks ERK activation and collagen production in isolated cardiac fibroblasts. Also reduces symptoms in a mouse model of dermatophyte-associated itch.

Mefloquine (Ro 215998), a quinoline antimalarial agent, is an anti-SARS-CoV-2 entry inhibitor. Mefloquine is also a K+ channel (KvQT1/minK) antagonist with an IC50 of ~1 μM. Mefloquine can be used for malaria, systemic lupus erythematosus, and cancer research.

MMPP is a novel VEGFR2 inhibitor with anti-inflammatory and potential anticancer activity, inhibits STAT3, inhibits angiogenesis via VEGFR2/AKT/ERK/NF-kappaB pathway, and can be used to alleviate myocardial injury.